Fairvalue-Calculator Fairvalue-Calculator
EN DE

Steminent Biotherapeutics Inc (7729) Fair Value & Analysis

Healthcare · TW · Market cap 5.8B TWD

Price82.80 TWD
Fair Value24.31 TWD
Upside-70.6%
Quality95/100
Evidence: Low Range 18.23 TWD – 30.38 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Steminent Biotherapeutics Inc (7729) currently trades at 82.80 TWD, while our model-based Fair Value estimate is 24.31 TWD — implying the stock looks roughly 70.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington's disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Steminent Biotherapeutics Inc (7729) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 24.31 TWD versus a price of 82.80 TWD — about −71% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 7729?
Our 21-model fair value for Steminent Biotherapeutics Inc is 24.31 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 82.80 TWD.
What is the quality score of 7729?
Steminent Biotherapeutics Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.